AB Science is developing two main compounds Masitinib and AB8939

A new independent publication confirms the role of masitinib as a potential therapy in pancreatic cancer

February 23, 2021

23/02/2021 – AB Science announces that a new independent publication confirms the role of masitinib as a potential therapy in pancreatic cancer

A new independent publication confirms that masitinib has anti-viral activity against the SARS-CoV-2 virus in vitro

January 25, 2021

25/01/2021 – AB Science announces that a new independent publication confirms that masitinib has anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating Covid-19

Boursorama interview of Alain Moussy, CEO of AB Science

December 23, 2020

23/12/2020 – Read the interview of Alain Moussy, CEO of AB Science, in Boursorama

Capital raise for a total amount of 15 million euros

December 21, 2020

21/12/2020 – AB Science announces today the success of its capital raise for a total amount of 15 million euros

Results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease

December 18, 2020

18/12/2020 – AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease

Masitinib in Alzheimer’s Disease Webcast Presentation

December 17, 2020

17/12/2020 – Presentation of the webcast held on December 17, 2020 on masitinib in Alzheimer’s Disease

positive phase 2B/3 readouts with masitinib

publications in peer-reviewed journals

patients enrolled in masitinib studies